BioCentury
ARTICLE | Company News

BZL Biologics L.L.C., Millennium deal

April 16, 2001 7:00 AM UTC

MLNM will use BZL's humanized J591 antibody to develop and commercialize both immunotoxin and radiolabeled antibodies targeting Prostate Specific Membrane Antigen ( PSMA). MLNM and BZL will jointly de...